6-oxoprostaglandin E derivatives, process for their production and their
pharmaceutical use
    4.
    发明授权
    6-oxoprostaglandin E derivatives, process for their production and their pharmaceutical use 失效
    6-氧代前列腺素E衍生物,其制备方法及其药物用途

    公开(公告)号:US5023273A

    公开(公告)日:1991-06-11

    申请号:US276502

    申请日:1988-11-23

    CPC分类号: C07C405/00

    摘要: The invention relates to 6-oxo-prostaglandin E.sub.1 derivatives of formula I, ##STR1## in which R.sup.1 means the radical COOR.sup.2 with R.sup.2 meaning a hydrogen atom, C.sub.1 -C.sub.10 alkyl, a C.sub.5 -C.sub.6 cycloalkyl or a C.sub.6 -C.sub.10 aryl group or a heterocyclic radical, or the radical CONHSO.sub.2 R.sup.5 as C.sub.1-10 alkyl, C.sub.5-6 cycloalkyl or C.sub.6-10 aryl,A means an E-configuration CH.dbd.CH or a --C.dbd.C group,W means a free or functionally modified hydroxymethylene group or a free or functionally modified group, and the OH group in each case can be in the alpha or beta position,D means a straight-chain or branched-chain alkylene group with 1-5 C atoms,E means a --C.dbd.C group or a C.sub.2 -C.sub.4 alkenylene group,R.sup.3 means C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 cycloalkyl or an optionally substituted C.sub.6 -C.sub.10 aryl group or a heterocyclic group,R.sup.4 means a free or functionally modified hydroxy group, and if R.sup.2 means a hydrogen atom, its salts with physiologically compatible bases as well as alpha, beta or gamma cyclodextrin clathrates of the compounds of formula I, process for their production and their pharmaceutical use.

    摘要翻译: PCT No.PCT / DE88 / 00151 Sec。 371日期1988年11月23日第 102(e)日期1988年11月23日PCT提交1988年3月11日PCT公布。 出版物WO88 / 07037 本发明涉及式I的6-氧代 - 前列腺素E1衍生物,其中R1表示具有R2的基团COOR2,其表示氢原子,C1-C10烷基,C5- C6环烷基或C6-C10芳基或杂环基,或基团CONHSO2 R5为C1-10烷基,C5-6环烷基或C6-10芳基,A表示E构型CH = CH或-C = C 基团,W表示游离或官能改性的羟基亚甲基或游离或官能改性的基团,并且每种情况下OH基团可以在α或β位置,D表示具有1-位的直链或支链亚烷基, 5 C原子,E表示-C = C基或C 2 -C 4亚烯基,R 3表示C 1 -C 10烷基,C 3 -C 10环烷基或任选取代的C 6 -C 10芳基或杂环基,R 4表示游离或 官能改性的羟基,并且如果R 2表示氢原子,则其与生理相容性碱的盐以及化合物的α,β或γ环糊精包合物 的式I,其生产过程及其药物用途。

    .DELTA.8- and .DELTA.9-prostaglandin derivatives, process for their
production and their pharmaceutical use
    5.
    发明授权
    .DELTA.8- and .DELTA.9-prostaglandin derivatives, process for their production and their pharmaceutical use 失效
    DELTA 8-和DELTA 9-前列腺素衍生物,其生产过程及其药物用途

    公开(公告)号:US5376683A

    公开(公告)日:1994-12-27

    申请号:US982111

    申请日:1992-11-25

    IPC分类号: C07C405/00 A61K31/557

    CPC分类号: C07C405/00

    摘要: The invention relates to .DELTA..sup.8 - and .DELTA..sup.9 -prostaglandin derivatives of formula I, ##STR1## in which means the radicals or , R.sup.1 means ##STR2## COOR.sup.4 or CONHR.sup.5, R.sup.2 and R.sup.3 respectively mean a hydrogen atom or a hydroxy group, and the OH group can be respectively in alpha- or beta- position,means a CH.sub.2 group, an O or S atom,W means hydrogen, --OR.sup.6, halogen, --CN--, --NO.sub.2, trifluoromethyl or COOR.sup.6, and if R.sup.4 means hydrogen, their salts with physiologically compatible bases, the alpha-, beta- or gamma- cyclodextrin clathrates, as well as the compounds of formula I encapsulated with liposomes, process for their production and their pharmaceutical use.

    摘要翻译: 本发明涉及式I的DELTA 8-和DELTA 9-前列腺素衍生物,其中R 1和R 3分别表示氢原子或羟基,R 1和R 3分别表示氢原子或羟基 基团,OH基团可以分别为α-或β-位,是指CH 2基团,O或S原子,W表示氢,-OR 6,卤素,-CN-,-NO 2,三氟甲基或COOR 6,如果 R4表示氢,它们与生理相容性碱的盐,α-,β-或γ-环糊精包合物,以及用脂质体包封的式I化合物,其制备方法及其药物用途。

    2-oxabicyclo(2,2,1)heptane derivatives and pharmaceutical
    6.
    发明授权
    2-oxabicyclo(2,2,1)heptane derivatives and pharmaceutical 失效
    2-OXABICYCLO(2,2,1)HEPTANE DERIVATIVES AND PHARMACEUTICAL

    公开(公告)号:US5235072A

    公开(公告)日:1993-08-10

    申请号:US679054

    申请日:1991-05-07

    摘要: The invention relates to 2-oxabicyclo[2.2.1]heptane derivatives of formula I ##STR1## as well as their enantiomers, in which, e.g., A means --(CH.sub.2).sub.n --, (E)-- or (Z)--CH.dbd.CH--, --C.tbd.C, --O-- or --S--,B means hydrogen, C.sub.1 -C.sub.10 alkyl, --OR.sup.2, halogen, --C.tbd.N, --N.sub.3, --COOR.sup.3,R.sup.1 means oxygen or a --CH.sub.2 group, ##STR2## Z means --(CH.sub.2).sub.p --, (E)--CH.dbd.CH--, --C.tbd.C--, W means a direct bond, a free or functionally modified hydroxymethylene group or a free or functionally modified ##STR3## in which the OH group can be respectively in alpha- or beta-position, D means a direct bond, a saturated alkylene group with 1-5 C atoms, a branched saturated or a straight-chain of branched unsaturated alkylene group with 2-5 C atoms,E means a direct bond, --C.tbd.C-- or --CH.dbd.CR.sup.7,R.sup.8 means hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 cycloalkyl, optionally substituted C.sub.6 -C.sub.12 aryl or a 5- or 6-member heterocyclic radical, andif R.sup.5 means hydrogen, their salts with physiologically compatible bases, as well as the alpha-, beta- or gamma-cyclodextrin clathrates, as well as the compounds of formula I encapsulated with liposomes, process for their production and the pharmaceutical agents containing these compounds.The compounds are thromboxane antagonists.

    摘要翻译: PCT No.PCT / DE89 / 00585 Sec。 371日期1991年5月7日 102(e)日期1991年5月7日PCT提交1989年9月7日PCT公布。 出版物WO90 / 02740 1990年3月22日。本发明涉及式I(I)的2-氧杂二环[2.2.1]庚烷衍生物及其对映异构体,其中例如A表示 - (CH 2)n - (E) - 或(Z)-CH = CH - , - C 3BOND C,-O-或-S-,B表示氢,C1-C10烷基,-OR2,卤素,-C3NN,-N3, COOR 3,R 1表示氧或-CH 2基,Z表示 - (CH 2)p - ,(E)-CH = CH-,-C 3BOND C-,W表示直接键,游离或官能改性的羟基亚甲基 基团或其中OH基团可以分别位于α或β位的游离或功能修饰的“IMAGE”,D表示直接键合,具有1-5个C原子的饱和亚烷基,支链饱和或直链, 具有2-5个C原子的支链不饱和亚烷基链,E表示直接键,-C 3 D或-CH = CR 7,R 8表示氢,C 1 -C 10烷基,C 3 -C 10环烷基,任选取代的C 6 -C 12芳基 或5或6元杂环基,如果R 5表示氢,则其与生理上相容的碱的盐,以及碱 ha-,β-或γ-环糊精包合物,以及用脂质体包封的式I化合物,其制备方法和含有这些化合物的药剂。 化合物是血栓素拮抗剂。